Mark Magbanua

17PUBLICATIONS
100CO-AUTHORS
Predictive and prognostic markersTumour immunologyCircuits and systemsCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Aug 20, 2026
Circulating tumor DNA concentration at diagnosis is a modifiable prognostic factor for distant metastatic recurrence in patients with high-risk breast cancer receiving neoadjuvant therapy.

|Dec 09, 2025
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.

Mark Jesus M Magbanua, Nayelis A Manon, Denise M Wolf

|Jun 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.

Denise M Wolf, Christina Yau, Michael Campbell

|Mar 26, 2025
MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer.

Wen Li, Natsuko Onishi, Jessica E Gibbs

|Mar 18, 2025
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis.

Wolfgang Janni, Thomas W P Friedl, Tracy C Yab

|Feb 05, 2025
Implantation of engineered adipocytes suppresses tumor progression in cancer models.

Hai P Nguyen, Kelly An, Yusuke Ito

Pageof 3

Frequent Collaborators

8 joint publications

Laura J Esserman

7 joint publications

Laura van 't Veer

6 joint publications

Wen Li

5 joint publications

Gillian L Hirst